Deerfield Management Company, L.P. (Series C) Vera Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,348,117 shares of VERA stock, worth $101 Million. This represents 1.81% of its overall portfolio holdings.
Number of Shares
3,348,117
Previous 1,050,000
218.87%
Holding current value
$101 Million
Previous $25.2 Million
212.76%
% of portfolio
1.81%
Previous 0.64%
Shares
5 transactions
Others Institutions Holding VERA
# of Institutions
203Shares Held
65.2MCall Options Held
1.58MPut Options Held
365K-
Avoro Capital Advisors LLC New York, NY6.3MShares$191 Million2.71% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.48MShares$135 Million0.01% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.43MShares$104 Million9.64% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$101 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY3.1MShares$93.7 Million3.85% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $818M
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...